Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2018 4
2019 4
2020 4
2021 5
2022 6
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial.
Kater AP, Levin MD, Dubois J, Kersting S, Enggaard L, Veldhuis GJ, Mous R, Mellink CHM, van der Kevie-Kersemaekers AF, Dobber JA, Poulsen CB, Frederiksen H, Janssens A, Schjødt I, Dompeling EC, Ranti J, Brieghel C, Mattsson M, Bellido M, Tran HTT, Nasserinejad K, Niemann CU. Kater AP, et al. Among authors: schjodt i. Lancet Oncol. 2022 Jun;23(6):818-828. doi: 10.1016/S1470-2045(22)00220-0. Lancet Oncol. 2022. PMID: 35654052 Clinical Trial.
Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia.
Niemann CU, Levin MD, Dubois J, Kersting S, Enggaard L, Veldhuis GJ, Mous R, Mellink CHM, Dobber JA, Poulsen CB, Frederiksen H, Janssens A, Schjødt I, Dompeling EC, Ranti J, Mattsson M, Bellido M, Tran HTT, Nasserinejad K, Kater AP. Niemann CU, et al. Among authors: schjodt i. Blood. 2021 Feb 25;137(8):1117-1120. doi: 10.1182/blood.2020008608. Blood. 2021. PMID: 33027809 Free article. Clinical Trial. No abstract available.
Triple-Drug Graft-versus-Host Disease Prophylaxis after HLA-Matched Unrelated Donor Nonmyeloablative Allogenic Hematopoietic Stem Cell Transplantation.
Wegener A, Andersen NS, Friis LS, Petersen SL, Schjødt I, Kornblit B, Sengeløv H, Gjærde LK. Wegener A, et al. Among authors: schjodt i. Transplant Cell Ther. 2023 Sep;29(9):575.e1-575.e6. doi: 10.1016/j.jtct.2023.05.022. Epub 2023 Jun 9. Transplant Cell Ther. 2023. PMID: 37301257 Free article. Clinical Trial.
Improved survival after allogeneic transplantation for acute lymphoblastic leukemia in adults: a Danish population-based study.
Gjærde LK, Rank CU, Andersen MK, Jakobsen LH, Sengeløv H, Olesen G, Kornblit B, Marquart H, Friis LS, Petersen SL, Andersen NS, Nielsen OJ, Toft N, Schjødt I. Gjærde LK, et al. Among authors: schjodt i. Leuk Lymphoma. 2022 Feb;63(2):416-425. doi: 10.1080/10428194.2021.1992620. Epub 2021 Oct 21. Leuk Lymphoma. 2022. PMID: 34672245
Pretransplantation vitamin A plasma levels and risk of acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Gjærde LK, Andersen NS, Friis LS, Kornblit B, Petersen SL, Schjødt I, Ostrowski SR, Sengeløv H. Gjærde LK, et al. Among authors: schjodt i. Bone Marrow Transplant. 2020 Jul;55(7):1457-1459. doi: 10.1038/s41409-019-0760-5. Epub 2019 Nov 26. Bone Marrow Transplant. 2020. PMID: 31772337 No abstract available.
Improved Outcomes after Allogenic Hematopoietic Stem Cell Transplantation with Fludarabine/Treosulfan for Patients with Myelodysplastic Syndromes.
Wedge E, Sengeløv H, Hansen JW, Andersen NS, Schjødt I, Petersen SL, Kornblit B, Grønbæk K, Friis LS. Wedge E, et al. Among authors: schjodt i. Biol Blood Marrow Transplant. 2020 Jun;26(6):1091-1098. doi: 10.1016/j.bbmt.2020.02.010. Epub 2020 Feb 20. Biol Blood Marrow Transplant. 2020. PMID: 32088368 Free article.
20 results